DiagnoCure has announced that its partner for the Previstage GCC colorectal cancer staging test Signal Genetics has reported the results of a new study at the 2012 American Society of Clinical Oncology Gastrointestinal Cancer Symposium held in San Francisco, US.
Previstage GCC colorectal cancer staging test provides prognostic information based on the tumour burden measured at the molecular level in the lymph nodes, a key prognostic factor to determine the risk of recurrence of cancer patients. The pooled individual data analysis involving 310 patients showed that the GCC levels allow an effective stratification of patients between those that are essentially cured and those at high risk of disease recurrence.
The study demonstrated that higher detection levels of GCC in lymph nodes were associated with increased risk of all-cause mortality, disease-specific survival, and disease-free survival. In the trial, the five-year recurrence risks were estimated at 11% and 32% for the low and high-risk groups respectively.
Earlier studies have shown that the GCC biomarker is a better predictor, than traditionally used factors, of disease recurrence in early stage colorectal cancer patients. In a recent study conducted in a subset of 181 stage II colon cancer patients, the Previstag GCC test classified one-third of patients as having a high risk of recurrence following surgery and two-thirds of patients at low risk of recurrence.
DiagnoCure is a life sciences company that develops and commercialises high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. It also has a strategic alliance with Gen Probe for the development and commercialisation of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. The CE-marked Progensa PCA3 test was recently approved in Canada and US.